Cellnovo gets CE Mark for first mobile diabetes system

Cellnovo has received CE Mark approval for the world's first mobile diabetes management system (photo), which includes an insulin patch pump, a wireless, touch screen handset with a built-in blood glucose monitor, as well as an extendable applications set.

The patch pump is the smallest and most precise ever developed, according to the company. And the handset wirelessly receives and transmits real-time data to a portal for patients and caregivers to use, eliminating the need for meticulous journals and ensuring optimal monitoring and treatment.

"Cellnovo has combined advanced mobile and medical technology which may create a paradigm shift in diabetes care," the University of Washington's Irl Hirsch says in a statement. "For the multitude of patients who could benefit from pump therapy, Cellnovo could be a game-changer."

The approval comes a week after Cellnovo announced a partnership with Johnson & Johnson's ($JNJ) LifeScan unit. Under the agreement, Cellnovo will integrate LifeScan's blood glucose monitoring technologies into the handset of its mobile diabetes management system.

Earlier this year, the company raised $48.4 million in a Series B financing led by Edmond de Rothschild Investment Partners. The company said it would use funds to commercialize its system and expand to new markets, adding that it hopes to enter the U.S. this year.

- see the Cellnovo release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.